Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/50115
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vassili C. | - |
dc.contributor.author | Parker C. | - |
dc.contributor.author | Hodgson A. | - |
dc.contributor.author | Rady K. | - |
dc.contributor.author | Fileming S. | - |
dc.contributor.author | Wei A. | - |
dc.date.accessioned | 2023-08-24T05:21:41Z | - |
dc.date.available | 2023-08-24T05:21:41Z | - |
dc.date.copyright | 2023 | - |
dc.date.issued | 2023-07-28 | en |
dc.identifier.citation | Supportive Care in Cancer. Conference: MASCC/JASCC/ISOO 2023 Annual Meeting. Nara Japan. 31(Supplement 1) (pp S255-S256), 2023. Date of Publication: June 2023. | - |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/50115 | - |
dc.description.abstract | Introduction Intensive chemotherapy for newly diagnosed acute myeloid leukemia and acute lymphoblastic leukemia is associated with short and long-term treatment-related morbidity and mortality, resulting from patient, disease, and treatment factors. The toxicity of treatment is well appreciated, and there is now increasing interest in understanding the impact of therapy on physical, psychological, social and fnancial (PPSF) functioning. It is hypothesised that identifying impaired PPSF functioning will improve awareness and assist in early identification and intervention strategies to improve patient outcomes. Methods A multidisciplinary team collaborated to implement a longitudinal follow-up program. Patients aged >=18 years post completion of intensive therapy for acute leukaemia, achieved morphological remission and not proceeding to allogenic stem cell transplant in first remission, are eligible to participate. Patients are reviewed 3-monthly for 24 months in a dedicated IMPROVE clinic where there is systematic collection of patient-reported outcomes (including quality of life, fatigue, anxiety and depression; sleep quality; sexual function and fnancial toxicity); physical and ftness assessments, preventative health and pathology collection (including cytokine assessments). Results Recruitment commenced in February 2019 and is ongoing; to date 28 patients have consented to participate and 6 patients have withdrawn due to disease relapse. The COVID-19 pandemic significantly impacted recruitment and the reviews at planned timepoints. Despite this, many patients have completed multiple visits (>130 total visits to date) and had clinical fndings resulting in intervention. The clinic has been positively received with high retention rates. However, the current format is resource intensive and would be unsustainable for routine implementation. Conclusions Preliminary fndings indicate that a dedicated clinic assessing for PPSF functioning recognises issues not identifed in routine care. After data analysis, it is envisioned that the assessments deemed most benefcial will become incorporated as part of an ongoing survivorship clinic. | - |
dc.publisher | Springer Verlag | - |
dc.relation.ispartof | Supportive Care in Cancer | - |
dc.subject.mesh | acute leukemia | - |
dc.subject.mesh | anxiety | - |
dc.subject.mesh | coronavirus disease 2019 | - |
dc.subject.mesh | depression | - |
dc.subject.mesh | intensive care | - |
dc.subject.mesh | leukemia | - |
dc.subject.mesh | pandemic | - |
dc.subject.mesh | quality of life | - |
dc.subject.mesh | sexual function | - |
dc.subject.mesh | sleep quality | - |
dc.subject.mesh | transplantation | - |
dc.subject.mesh | cytokine | - |
dc.title | Integrated management of post-remission leukaemia to optimise longevity and enhance quality of life: the improve longitudinal study. | - |
dc.type | Conference Abstract | - |
dc.identifier.affiliation | Monash University - School of Clinical Sciences at Monash Health | - |
dc.description.conferencename | MASCC/JASCC/ISOO 2023 Annual Meeting | - |
dc.description.conferencelocation | Nara, Japan | - |
dc.type.studyortrial | Observational study (cohort, case-control, cross sectional, or survey) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1007/s00520-023-07786-4 | - |
local.date.conferencestart | 2023-06-22 | - |
dc.identifier.institution | (Vassili, Fileming) Alfred Health, Department of Malignant Haematology and Stem Cell Transplantation, Melbourne, Australia | - |
dc.identifier.institution | (Parker) Monash University, School of Clinical Sciences at Monash Health, Melbourne, Australia | - |
dc.identifier.institution | (Hodgson) Consumer Representative, Melbourne, Australia | - |
dc.identifier.institution | (Rady) Canberra Hospital, Department of Haematology, Canberra, Australia | - |
dc.identifier.institution | (Wei) Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia | - |
local.date.conferenceend | 2023-06-24 | - |
dc.identifier.affiliationmh | (Parker) Monash University, School of Clinical Sciences at Monash Health, Melbourne, Australia | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairetype | Conference Abstract | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
Appears in Collections: | Conferences |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.